Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1988-08-12
1992-04-07
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514963, 514921, 514872, 514 12, 930141, 424499, A61K 3702
Patent
active
051028727
ABSTRACT:
Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and mixed with a release-modulating amount of humen serum albumin. The microcapsules are administered parenterally, and release an effective amount of conjugated IL-2 continuously over a period of 14-30 days. These microcapsules are also effective in the treatment of cancer in mammals.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4526938 (1985-07-01), Churchill
patent: 4571336 (1986-02-01), Houck et al.
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4818769 (1989-04-01), Nunberg
Beck et al., 1983, "Long-Acting Steroid Contraception" Raven Press, NY.
Beck et al., 1985, Adv. Contracept. 1:119-129.
Cowsar et al., 1985, Methods in Enzymology 112:101-116.
Reed et al., 1984, J. Immunology 133:3333-3337.
Hora et al., Bio/Technology, 8, 755-758 (1990).
Hora et al., Pharmaceutical Research, 7(11), 1190-1194 (1990).
Hora et al., Pacific Polymer Conference, 1, 519-520 (1989).
Gilley Richard M.
Hudson Michael E.
Nunberg Jack H.
Singh Maninder
Taforo Terrance A.
Cetus Corporation
Green Grant
Griffin Ronald W.
Gruber Lewis S.
McGarrigle Philip L.
LandOfFree
Controlled-release formulations of interleukin-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled-release formulations of interleukin-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled-release formulations of interleukin-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1895388